These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 19211937)
1. The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration. Porcellini S; Alberici L; Gubinelli F; Lupo R; Olgiati C; Rizzardi GP; Bovolenta C Blood; 2009 Apr; 113(15):3443-52. PubMed ID: 19211937 [TBL] [Abstract][Full Text] [Related]
2. Chim3 confers survival advantage to CD4+ T cells upon HIV-1 infection by preventing HIV-1 DNA integration and HIV-1-induced G2 cell-cycle delay. Porcellini S; Gubinelli F; Alberici L; Piovani BM; Rizzardi GP; Bovolenta C Blood; 2010 May; 115(20):4021-9. PubMed ID: 20220118 [TBL] [Abstract][Full Text] [Related]
3. T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner. Vallanti G; Lupo R; Federico M; Mavilio F; Bovolenta C Mol Ther; 2005 Oct; 12(4):697-706. PubMed ID: 16039909 [TBL] [Abstract][Full Text] [Related]
4. gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants. D'Aloja P; Olivetta E; Bona R; Nappi F; Pedacchia D; Pugliese K; Ferrari G; Verani P; Federico M J Virol; 1998 May; 72(5):4308-19. PubMed ID: 9557721 [TBL] [Abstract][Full Text] [Related]
5. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. Refsland EW; Hultquist JF; Luengas EM; Ikeda T; Shaban NM; Law EK; Brown WL; Reilly C; Emerman M; Harris RS PLoS Genet; 2014 Nov; 10(11):e1004761. PubMed ID: 25411794 [TBL] [Abstract][Full Text] [Related]
6. Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages. Ao Z; Wang X; Bello A; Jayappa KD; Yu Z; Fowke K; He X; Chen X; Li J; Kobinger G; Yao X Hum Gene Ther; 2011 Oct; 22(10):1225-37. PubMed ID: 21182427 [TBL] [Abstract][Full Text] [Related]
7. APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study. Hosseini I; Mac Gabhann F PLoS One; 2013; 8(5):e63984. PubMed ID: 23724012 [TBL] [Abstract][Full Text] [Related]
8. Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. Rosenzweig M; Marks DF; Hempel D; Lisziewicz J; Johnson RP J Virol; 1997 Apr; 71(4):2740-6. PubMed ID: 9060627 [TBL] [Abstract][Full Text] [Related]
9. Regulation of HIV-1 infection in cells derived from purified CD34+ cells through manipulation of APOBEC3G expression. Heinzelmann A; Stein S; Köhl U; Dietrich U; von Briesen H Curr HIV Res; 2010 Oct; 8(7):554-63. PubMed ID: 20642434 [TBL] [Abstract][Full Text] [Related]
10. Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation. Ma L; Zhang Z; Liu Z; Pan Q; Wang J; Li X; Guo F; Liang C; Hu L; Zhou J; Cen S Sci Rep; 2018 May; 8(1):8067. PubMed ID: 29795228 [TBL] [Abstract][Full Text] [Related]
11. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication. Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381 [TBL] [Abstract][Full Text] [Related]
12. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1. Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 Escape from Small-Molecule Antagonism of Vif. Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M mBio; 2019 Feb; 10(1):. PubMed ID: 30808702 [TBL] [Abstract][Full Text] [Related]
14. Long-term passage of Vif-null HIV-1 in CD4 Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088 [TBL] [Abstract][Full Text] [Related]
15. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Bai J; Banda N; Lee NS; Rossi J; Akkina R Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773 [TBL] [Abstract][Full Text] [Related]
16. The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest. Wang J; Shackelford JM; Selliah N; Shivers DK; O'Neill E; Garcia JV; Muthumani K; Weiner D; Yu XF; Gabuzda D; Finkel TH DNA Cell Biol; 2008 May; 27(5):267-77. PubMed ID: 18462066 [TBL] [Abstract][Full Text] [Related]
17. HIV-1 viral infectivity factor interacts with microtubule-associated protein light chain 3 and inhibits autophagy. Borel S; Robert-Hebmann V; Alfaisal J; Jain A; Faure M; Espert L; Chaloin L; Paillart JC; Johansen T; Biard-Piechaczyk M AIDS; 2015 Jan; 29(3):275-86. PubMed ID: 25490467 [TBL] [Abstract][Full Text] [Related]
18. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. Gabuzda DH; Lawrence K; Langhoff E; Terwilliger E; Dorfman T; Haseltine WA; Sodroski J J Virol; 1992 Nov; 66(11):6489-95. PubMed ID: 1357189 [TBL] [Abstract][Full Text] [Related]
19. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers. Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111 [TBL] [Abstract][Full Text] [Related]